by Insomnia is a prevalent issue among long-term dialysis patients, affecting up to 50% of individuals undergoing this treatment. Given the detrimental effects of insomnia on quality of life, researchers have been exploring different interventions to address this condition. Two commonly used treatments for insomnia are cognitive behavioral therapy for insomnia (CBT-I) and the medication trazodone. However, a recent clinical trial published in the Annals of Internal Medicine has found that neither CBT-I nor trazodone was more effective than a placebo in improving mild to moderate chronic insomnia in long-term dialysis patients.
The trial involved 126 participants undergoing hemodialysis and experiencing chronic insomnia. These individuals were randomly assigned to receive CBT-I, trazodone, or a placebo for a duration of six weeks. The severity of insomnia was assessed using the Insomnia Severity Index (ISI) questionnaire at the beginning of the trial, as well as at seven and 25 weeks.
Surprisingly, the study found that there was no significant difference in the change of ISI scores between the groups that received CBT-I, trazodone, or the placebo. This suggests that these interventions were equally ineffective in improving insomnia symptoms in long-term dialysis patients. However, it’s worth noting that participants using trazodone experienced more serious adverse events compared to those in the other groups.
The results of this study are important considering the high prevalence of insomnia among long-term dialysis patients and the significant impact it has on their overall well-being. Despite the unsuccessful outcomes with CBT-I and trazodone, researchers emphasize the need for more trials to explore alternative therapies for managing insomnia in this population.
In an accompanying editorial, Dr. Ronald B. Postuma highlights the complexity of treating insomnia in long-term dialysis patients. He notes that the lack of efficacy observed with CBT-I in this study is surprising, given the strong evidence supporting its effectiveness in primary insomnia among the general population. This suggests that the underlying causes of insomnia in long-term dialysis patients may differ, making CBT-I less effective in this context.
Dr. Postuma also suggests that future studies should examine medications specifically developed for insomnia and interventions targeting conditions such as restless legs and neuropathic pain, which could contribute to insomnia symptoms in this patient population.
In conclusion, the findings of this study indicate that both CBT-I and trazodone are not effective in improving insomnia among long-term dialysis patients. Given the high burden of insomnia experienced by these individuals and the importance of finding effective treatments, further research is needed to identify alternative therapies that can effectively manage insomnia in this population.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
